As mentioned before, established peritoneal fibrosis occurs in mice after longer CHX treatments, where the MMT process contributes to PM damage development through signaling pathways as the transforming growth factor-β/suppressor of mothers against decapentaplegic (TGF-β/SMAD). Here, TGFB1 is linked to Peritoneal Fibrosis.